Clinical Gastroenterology and Hepatology
Volume 7, Issue 10 , Pages 1139-1140, October 2009

Reply

  • Corey A. Siegel, MD, MS

      Affiliations

    • Dartmouth-Hitchcock IBD Center and Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
    • The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, New Hampshire
    • ,
  • Bruce E. Sands, MD, MS

      Affiliations

    • MGH Crohn's and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
    • ,
  • Sadie M. Marden, MPH

      Affiliations

    • The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, New Hampshire

published online 24 August 2009.

We thank Peyrin-Biroulet and colleagues for their comments regarding our manuscript. They raise useful considerations; however, we believe that we have performed the best possible analysis with currently available data.

 

 Conflicts of interest These authors disclose the following: Dr Siegel has served as a consultant or on a scientific advisory board for Abbott, Elan, and UCB; received honoraria for speaking from Abbott, P&G, and UCB; and received grant support from P&G. Dr Sands has served either as a consultant or on a scientific advisory board for Abbott, Biogen/IDEC, Bristol-Myers Squibb, Centocor, Elan, Millenium Pharmaceuticals, Novartis Pharmaceuticals, Otsuka America Pharmaceuticals Inc, and UCB; received honoraria for speaking from Abbott, Shering-Plough, and UCB; and received grant support from Abbott, Bristol-Myers Squibb, Centocor, Elan, Millenium Pharmaceutical, Novartis Pharmaceuticals and Otsuka America Pharmaceutical Inc. The remaining author discloses no conflicts.

 Funding Dr Siegel is supported by a CCFA career development award and by grant K23DK078678 from the National Institute of Diabetes and Digestive and Kidney Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases or the National Institutes of Health.

PII: S1542-3565(09)00779-4

doi:10.1016/j.cgh.2009.08.017

Refers to article:

  • Insufficient Evidence to Conclude Whether Anti–Tumor Necrosis Factor Therapy Increases the Risk of Lymphoma in Crohn's Disease , 25 May 2009

    Laurent Peyrin–Biroulet, Jean–Frederic Colombel, William J. Sandborn
    Clinical Gastroenterology and Hepatology October 2009 (Vol. 7, Issue 10, Page 1139)

Clinical Gastroenterology and Hepatology
Volume 7, Issue 10 , Pages 1139-1140, October 2009